BRAF mutation can also represent a therapeutic target in metastatic CRC but targeting BRAF will also require the blockade of other pathways including, EGFR, MEK and PI3K differently from melanoma and non-small cell lung cancer where BRAF inhibition produces therapeutic benefits [33]. This evidence concerns the gene BRAF and melanoma.